Diets · Metabolic & Cardiometabolic
LDL cholesterol is-a-cardiovascular-risk-factor-even-on a low-carb or carnivore diet
In plain terms: Is high LDL on a carnivore diet still a heart concern?
Yes — LDL/ApoB is causal for atherosclerosis by genetics and trials; there is no evidence carnivore-induced high LDL is exempt, so Baker's dismissal is not supported.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Sanchez-Quesada 2026 · Front Endocrinol | observational | supports | moderate | Cumulative lifetime LDL-C exposure (cohorts, FH, MR) causally drives CV risk regardless of when measured. |
| Budoff M, ... Norwitz NG, et al. (KETO Trial) 2024 · JACC Adv | observational | mixed | moderate | KETO trial: lean-mass-hyper-responders on carbohydrate restriction develop very high LDL-C; framed by low-carb advocates as possibly benign, but plaque outcomes remained under study — does not exonerate high LDL. |
| Norwitz NG, Soto-Mota A, et al. 2022 · Front Endocrinol | n-of-1 | mixed | low | Single LMHR case with LDL-C to 545 mg/dL and no CT-angiography plaque after ~2 years — an anecdotal n-of-1 offered against LDL concern; hypothesis-generating only, not evidence of safety. |
| Soto-Mota A, Norwitz NG, ... Budoff M 2025 · JACC Adv (RETRACTED 2026) | observational | mixed | low | Keto lean-mass hyper-responders: baseline plaque predicted progression; authors argue ApoB did not — small, advocacy-linked, contested (Feldman-Norwitz network). ⚠️ RETRACTED — not counted |
| Kalra 2026 · J Clin Lipidol | meta-analysis | supports | high | Meta-analysis of primary-prevention statin trials: each 1 mmol/L LDL-C reduction lowers major adverse cardiovascular events, confirming LDL-C as a causal, modifiable ASCVD risk factor. |
| Sabatine 2018 · JAMA Cardiology | meta-analysis | supports | high | Meta-analysis showing further LDL-C lowering reduces major vascular events even from already very low baseline LDL-C — 'lower is better,' supporting causality. |
| Cooper ID, ... Norwitz NG, Soto-Mota A 2023 · Front Endocrinol | mechanism | mixed | low | Lipid Energy Model: in lean people carb-restriction raises LDL via lipid trafficking — explains the rise, does not prove it is benign. |
| Pirillo 2026 · Pharmacol Rev | observational | supports | high | Review synthesizing genetics, Mendelian randomization and trials: cumulative LDL-C exposure is causal for lifelong ASCVD risk and lowering it reduces events. |
| Wang 2022 · Circ Cardiovasc Qual Outcomes | meta-analysis | supports | high | Each mmol/L LDL-C lowering cuts major CV events; Mendelian randomization shows lifetime LDL causally raises risk. |
| Kronenberg 2022 · Eur Heart J | observational | supports | high | EAS consensus (large genetic + epidemiologic data) states elevated ApoB-containing lipoproteins are causal for ASCVD and confer risk even at low LDL-C, reinforcing that high LDL/ApoB is a genuine concern. |
| Lincoff 2024 · J Am Coll Cardiol | RCT | supports | high | CLEAR Outcomes: bempedoic-acid LDL-C lowering (~21%) in statin-intolerant patients cut major adverse cardiovascular events ~13%, independent of statins, reinforcing LDL causality. |
| Gencer 2020 · Lancet | meta-analysis | supports | high | Meta-analysis of RCTs in older patients: LDL-lowering therapy reduces major vascular events per 1 mmol/L LDL-C reduction, including in adults over 75. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.